Abstract: Disclosed are antimicrobial releasing agents, methods of preparing the antimicrobial releasing agents, and entrained polymers containing antimicrobial releasing agents. The antimicrobial releasing agent is prepared with an acidified hydrophilic material with a pH below 3.5 as a carrier, an active compound, and a trigger. The entrained polymer of the invention releases an antimicrobial agent in gas form, such as ClO2, optionally over a range of concentration from 150 ppm to 1800 ppm per gram of the entrained polymer under certain tested conditions.

Abstract: The present invention relates to a film comprising an alginate salt of a monovalent cation or a mixture of alginate salts containing at least one alginate salt of a monovalent cation, and an antagonist of an opioid receptor, an inverse agonist of an opioid receptor, or a prodrug thereof. The present invention further relates to methods for manufacturing such a film, and the use of such a film in the treatment of a human patient, in particular the use of such a film in the treatment of the effects of acute opioid overdose, or the use of such a film in reducing the risk of opioid abuse.

Abstract: The drug-containing fat emulsion of the present invention, which comprises at least a slightly water soluble drug, an oil or fat, an emulsifier, and water as components, is characterized by having a content of the oil or fat of 2 to 120 mg/mL (excluding 2 mg/mL), having a weight ratio of the drug to the oil or fat (drug/(oil or fat)) of 0.001 to 20 (provided that the total content of the drug and the oil or fat is at most 125 mg/mL), having a content of lecithin as the emulsifier of 50 to 200 mg/mL (in which 50% by weight or less of the used lecithin is optionally replaced by an emulsifier other than lecithin), and having a turbidity of 0.5 or lower.

Abstract: The present invention provides a ready to use stable aqueous dosage form of norepinephrine comprising an aqueous solution of norepinephrine or its pharmaceutically acceptable salt, one or more sulfite antioxidants and an ion chelator. The present invention also provides an infusion container filled with an aqueous solution of norepinephrine or its pharmaceutically acceptable salt, wherein the said solution is stable for a prolonged period of time and can be terminally sterilized by autoclaving.

Abstract: Non-aqueous dentifrice compositions comprising an alkaline earth metal acetate salt such as strontium acetate and/or an alkaline earth metal nitrate salt such as strontium nitrate; a carboxyvinyl polymer and a humectant.

Abstract: Stable wood preservative formulations comprising an amine copper complex, an azole compound, a cationic surfactant, and optionally, an organic solvent, are disclosed. The wood preservative formulations exhibit long-term stability and remain homogeneous, without the need for agitation.

Abstract: Provided are surprisingly effective methods for inactivating pathogens, and for producing highly immunogenic vaccine compositions containing an inactivated pathogen rendered noninfectious by exposure to a Fenton reagent, or by exposure to a Fenton reagent or a component thereof in combination with a methisazone reagent selected from the group consisting of methisazone, methisazone analogs, functional group(s)/substructure(s) of methisazone, and combinations thereof. The methods efficiently inactivate pathogens, while substantially retaining pathogen antigenicity and/or immunogenicity, and are suitable for inactivating pathogens, or for the preparation of vaccines for a wide variety of pathogens with genomes comprising RNA or DNA, including viruses and bacteria. Also provided are highly immunogenic inactivated vaccine compositions prepared by using any of the disclosed methods, and methods for eliciting an immune response in a subject by administering such vaccine compositions.

Abstract: Oral care compositions and methods for the same are provided herein. The oral care composition may include an orally acceptable vehicle, a peroxide whitening agent, and one or more gelling agents. The gelling agents may include a fatty acid. The gelling agents may be free or substantially free of fatty alcohols. The gelling agents may include at least one of palmitic acid, stearic acid, or mixtures thereof.

Abstract: A dentifrice composition with tin, calcium, and a pH of greater than 7. A dentifrice composition with tin, fluoride, calcium abrasive, water, and a pH of greater than 7. Dentifrice compositions with a high tin ion availability. Dentifrice compositions comprising stannous fluoride and/or stannous chloride in combination with calcium carbonate.

Abstract: An oral care composition with a tin, polyol with five or six carbon atoms, polyol with seven or more hydroxyl functional groups, and a pH of greater than 7. An oral care composition with a tin ion source, a fluoride ion source, a polyol with five or six carbon atoms, a non reducing sugar or sugar alcohol with seven or more hydroxyl functional groups, and a pH of greater than 7. Oral care compositions with a high tin ion availability.

Abstract: An oral care composition with tin, polyol with five or more carbon atoms, water, and a pH of greater than 7. An oral care composition with a tin ion source, a fluoride ion source, a polyol with five or more carbon atoms, water, and a pH of greater than 7. Oral care compositions with a high tin ion availability.

Abstract: The invention is directed to hierarchical aluminosilicates that contain both micro- and meso-pores, to methods for loading and delivering poorly soluble antioxidants such as CoQ10 and curcumin to subjects, and to a top-down method for producing hierarchical aluminosilicates.

Abstract: The invention pertains to the use of therapeutically effective amounts of (a) (i) vitamin C and/or selenium and (ii) at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA), or esters thereof; or (b) (i) vitamin C and/or selenium and (iii) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof; or (c) a combination of (i), (ii) and (iii); wherein (a), (b) or (c) optionally further comprises vitamin E, in the manufacture of a product for therapeutically improving synaptic connectivity and/or therapeutically supporting memory and/or cognitive function in a human subject in need thereof.

Abstract: Described herein are methods of treating a proliferative disease in a subject by administering a DNA-damaging agent and between about 8 and about 48 hours later administering to the subject a DNA-PK inhibitor. Exemplary DNA-PK inhibitors are represented by Formula (B-I): and by pharmaceutically acceptable salts thereof, wherein R1, Q, Ring A, and Ring B are as defined herein.

Abstract: An oil-based composition comprises a glyceride of medium-chain fatty acids, at least one essential oil selected from the group consisting of cinnamon oil, oregano oil, avocado oil, coconut oil and apricot oil, and optionally cinnamon bark. The medium-chain fatty acid comprises about 6 to 12 carbon atoms. The oil-based composition may be used for oral hygiene applications, weight control applications, skin care applications, or treatment of Staphylococcus aureus infection.

Abstract: Provided herein are methods of increasing mucus clearance in a subject having decreased mucus clearance. Also provided are methods of treating or preventing a respiratory disorder.

Abstract: A laminate patchable to a living body and that includes a pressure-sensitive adhesive layer for patching to the living body and a substrate layer disposed on a one-side surface in a thickness direction of the pressure-sensitive adhesive layer and supporting the pressure-sensitive adhesive layer. The pressure-sensitive adhesive layer contains a first carboxylic acid ester and the substrate layer contains a second carboxylic acid ester.

Abstract: Provided herein are dietary supplement compositions comprising a plurality of beadlets and an oil. Provided herein are also dietary supplement compositions comprising a plurality of mini-tabs and oil. The beadlets or mini-tabs comprise at least one nutrient that is miscible in aqueous solution, and the oil comprises at least one fat-soluble nutrient. The composition may be contained within one or more capsules, and be packaged with a scented insert.

Abstract: A method of treating or preventing a respiratory disease in a pig is described that includes administering to the pig in need thereof an effective amount of meloxicam or a pharmaceutically acceptable salt thereof.

Abstract: The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention provides lipids having the following structure XXXIII, wherein: R1 and R2 are each independently for each occurrence optionally substituted C10-C30 alkyl, optionally substituted C10-C30 alkenyl, optionally substituted C10-C30 alkynyl, optionally substituted C10-C30 acyl, or -linker-ligand; R3 is H, optionally substituted C1-C10 alkyl, optionally substituted C2-C10 alkenyl, optionally substituted C2-C10 alkynyl, alkylhetrocycle, alkylphosphate, alkylphosphorothioate, alkylphosphorodithioate, alkylphosphonates, alkylamines, hydroxyalkyls, ?-aminoalkyls, ?-(substituted)aminoalkyls, ?-phosphoalkyls, ?-thiophosphoalkyls, optionally substituted polyethylene glycol (PEG, mw 100-40K), optionally substituted mPEG (mw 120-40K), heteroaryl, heterocycle, or linker-ligand; and E is C(O)O or OC(O).